Scientists think a popular diabetes drug might be quietly reshaping the fight against cancer.

A groundbreaking new study suggests that drugs like Ozempic, originally designed for diabetes and weight loss, may have an unexpected bonus: cutting the risk of several major cancers. Researchers have found strong links between long-term use of GLP-1 medications and lower rates of colorectal, liver, and pancreatic cancers.
If confirmed, it could mark one of the most surprising side effects in modern medicine — one that redefines prevention itself.












